Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v13-EN Version v3-EN
Language English English
Date Updated 2024-05-14 2023-09-21
Drug Identification Number 02162423 02162423
Brand name NAPROSYN NAPROSYN
Common or Proper name Naproxen sodium tablets USP Naproxen sodium tablets USP
Company Name ATNAHS PHARMA UK LIMITED ATNAHS PHARMA UK LIMITED
Ingredients NAPROXEN NAPROXEN
Strength(s) 500MG 500MG
Dosage form(s) TABLET (ENTERIC-COATED) TABLET (ENTERIC-COATED)
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100s 100s
ATC code M01AE M01AE
ATC description ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2023-09-21 2023-09-21
Estimated end date 2024-07-15 2023-12-20
Actual end date
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Manufacturing delays Manufacturing delays
Health Canada comments